课题基金 / 基金详情

Interrogation of the Cellular Pathogenesis of Pulmonary Hypertension

Interrogation of the Cellular Pathogenesis of Pulmonary Hypertension
肺动脉高压的细胞发病机制的探讨
批准号:
8046180
负责人:
ARI L ZAIMAN
金额:
$20.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-01-01 至 2012-12-31

项目摘要

项目成果

ARI L ZAIMAN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):肺动脉高压(PH)是一种进行性疾病,定义为平均肺动脉压升高超过25 mm Hg,导致右心衰竭和显著的死亡风险。TGF β超家族通路的两个成员骨形态发生蛋白受体II(BMPR II)和TGF β受体I(ALK 1)的遗传改变与PH的发病机制有关。尽管TGF β通路具有遗传和功能意义,但目前尚不清楚TGF β信号转导的失调如何导致PAH。我们推测PAH的发生是由于内皮细胞内TGF信号的不平衡。具体地,内皮细胞中增强的TGF信号传导促进表型变化,其允许细胞经历内皮-间充质转化并有助于平滑肌或肌成纤维细胞群体。该项目解决了肺动脉高压中的一个基本问题,即TGF β信号传导改变导致PH发病机制的机制。参与和多种细胞类型(内皮、平滑肌和外膜成纤维细胞)它能够影响并可能影响肺动脉高压的发展。为了开始解决分子途径,本项目提出研究TGF?信号转导在内皮细胞中的作用。我们将依靠内皮细胞诱导的TGF?受体II缺失和PH的成熟缺氧模型来证明内皮细胞TGF?信号传导在PH发展中的作用。内皮-间充质转化的特征将是遗传标记内皮细胞并在暴露于慢性缺氧后跟踪其命运。最后,我们将证明TGF β信号是内皮-间充质转化所必需的,并测试TGF β介导的转化的新型抑制剂。了解这种情况发生的分子机制可以深入了解人类PAH的启动和新的治疗靶点的开发。
英文摘要
DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PH), a progressive disease defined by an elevation in the mean pulmonary artery pressure above 25 mm Hg, leads to right heart failure and a significant risk of death. Genetic alterations in two members of the TGF ¿ superfamily pathways, bone morphogenetic protein receptor II (BMPR II) and the TGF-¿ receptor I, ALK1, have been implicated in the pathogenesis of PH. Despite the genetic and functional significance of the TGF pathway, it is unclear how dysregulation of TGF signaling results in PAH. We hypothesize that the development of PAH results from an imbalance in TGF signaling within endothelial cells. Specifically, enhanced TGF signaling in endothelial cells promotes a phenotypic change that allows the cells to undergo endothelial-mesenchymal transition and contribute to the smooth muscle or myofibroblast cell population. This project addresses one of the fundamental questions in pulmonary hypertension, the mechanism by which altered TGF ¿ signaling contributes to the pathogenesis of PH. The complexity of this question is amplified by the myriad of cellular processes in which TGF ¿ participates and the multiple cell types (endothelial, smooth muscle, and adventitial fibroblasts) it is capable of affecting and which may influence the development of pulmonary hypertension. In order to begin addressing the molecular pathway, this project proposes to study the role of TGF ¿ signaling in endothelial cells. We will rely on an endothelial cell inducible deletion of TGF ¿ receptor II and the well-established hypoxic model of PH to demonstrate the role of endothelial cell TGF ¿ signaling in the development of PH. Endothelial-mesenchymal transition will be characterized by genetically tagging endothelial cells and following their fate after exposure to chronic hypoxia. Finally, we will demonstrate that TGF ¿ signaling is required for endothelial-mesenchymal transition and test a novel inhibitor of TGF ¿ mediated transition. Understanding the molecular mechanism by which this occurs can provide insight into the initiation of human PAH and the development of novel therapeutic targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modifying Genes in Pulmonary Hypertension
  • 批准号:
    6758374
  • 项目类别:
  • 资助金额:
    $13.31万
  • 财政年份:
    2004
  • 负责人:
    ARI L ZAIMAN
  • 依托单位:
Modifying Genes in Pulmonary Hypertension
  • 批准号:
    7086198
  • 项目类别:
  • 资助金额:
    $13.31万
  • 财政年份:
    2004
  • 负责人:
    ARI L ZAIMAN
  • 依托单位:
Modifying Genes in Pulmonary Hypertension
  • 批准号:
    7446722
  • 项目类别:
  • 资助金额:
    $13.31万
  • 财政年份:
    2004
  • 负责人:
    ARI L ZAIMAN
  • 依托单位:
Modifying Genes in Pulmonary Hypertension
  • 批准号:
    6901124
  • 项目类别:
  • 资助金额:
    $13.31万
  • 财政年份:
    2004
  • 负责人:
    ARI L ZAIMAN
  • 依托单位:
海外基金